Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years

International Journal of Biochemistry and Cell Biology

Volumn 45, Issue 9, 2013, Pages 1987-1996

  Liu, Bo ^a   Wen, Xin ^a   Huang, Canhua ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

HBV therapy; HBx protein; Hepatitis B virus; Hepatocellular carcinoma; In vivo model

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR; ADEFOVIR DIPIVOXIL; CASPASE 6; CASPASE 8; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; LAGOCICLOVIR; LAMIVUDINE; MITOGEN ACTIVATED PROTEIN KINASE; PRADEFOVIR; RECOMBINANT HEPATITIS B VACCINE; STEROID RECEPTOR COACTIVATOR 3; TELBIVUDINE; TENOFOVIR; VALTORCITABINE; VIRUS DNA;

ANTIVIRAL ACTIVITY; CHIMPANZEE; DNA METHYLATION; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; MYOPATHY; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; REVIEW; SCANDENTIA; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS REPLICATION;

HEPADNAVIRIDAE; HEPATITIS B VIRUS;

3,5-DIETHOXYCARBONYL-1,4-DIHYDROCOLLIDINE-TREATED; 5-LIPOXYGENASE; 5-LOX; AFP; ALANINE AMINOTRANSFERASE; ALDEHYDE DEHYDROGENASE 1; ALDH1; ALL; ALT; ANDROGEN RECEPTOR; AR; ASPARTATE AMINOTRANSFERASE; AST; C/EBP-Β; CADHERIN-1; CCAAT ENHANCER BINDING PROTEIN Β; CCCDNA; CD8T LYMPHOCYTES; CDH1; CHB; CHEMOKINE (C-X-C MOTIF) RECEPTOR 1; CHRONIC HEPATITIS B; CIITA; CLASS II TRANSACTIVATOR; CORE PROMOTER; CORTICOTROPIN-RELEASING HORMONE RECEPTOR 2; COVALENTLY CLOSED CIRCULAR DNA; CP; CREB; CRHR2; CTLS; CXCR1; CYCLIC ADENOSINE MONOPHOSPHATE (CAMP) RESPONSE ELEMENT-BINDING PROTEIN; DDC; DIPHTHERIA-TETANUS-PERTUSSIS; DTP; FAK; FARNESOID X RECEPTOR ALPHA; FDA; FOCAL ADHESION KINASE; FOOD AND DRUG ADMINISTRATION; FXRA; HB; HBCAG; HBEAG; HBIG; HBSAG; HBV; HBV THERAPY; HBX; HBX PROTEIN; HCC; HDAC1; HEME OXYGENASE-1; HEPATITIS B; HEPATITIS B CORE ANTIGEN; HEPATITIS B E ANTIGEN; HEPATITIS B IMMUNE GLOBULIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; HEPATITIS B X PROTEIN; HEPATOCELLULAR CARCINOMA; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEINS K; HISTONE DEACETYLASE 1; HNRNP K; HO-1; IFN-Α; IFNAR1; IL; IN VIVO MODEL; INTERFERON ALPHA; INTERLEUKIN; JAK; JANUS KINASE; LYMPHOBLASTIC LEUKEMIA; MACROPHAGIC MYOFASCIITIS; MAPK; METASTASIS-ASSOCIATED PROTEIN 1; MICRORNA; MIRNA; MITOGEN-ACTIVATED PROTEIN KINASE; MMF; MTA1; NHP; NON-HUMAN PRIMATES; OPEN READING FRAMES; OPN; ORFS; OSTEOPONTIN; PC; PEG; PH; PKC; POLYETHYLENE GLYCOL; PORTAL HYPERTENSION; PP1; PPIS; PRECORE; PROTEIN KINASE C; PROTEIN PHOSPHATASE 1; PROTEIN-PROTEIN INTERACTIONS; RNA INTERFERENCE; RNAI; SECRETED PHOSPHOPROTEIN-1; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISMS; SNPS; SPP1; STAT; TATA BINDING PROTEIN; TBP; TGF; TNF; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; TYPE I INTERFERON (IFN-ALPHA/BETA) RECEPTOR 1; WHV; WOODCHUCK HEPATITIS VIRUS; Α-FETOPROTEIN;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; VIRUS REPLICATION;

EID: 84885095261     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2013.06.017     Document Type: Review

References (130)

1. Akyildiz M, Gunsar F, Ersoz G, Karasu Z, Ilter T, Batur Y, et al. Adefovirdipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Digestive Diseases and Sciences 2007; 52:3444-7. (Pubitemid 350077178)
2. Almajhdi FN, Al-Ahdal M, Abdo A.A., Sanai FM, Al-Anazi M, Khalaf N, et al Single nucleotide polymorphisms in CXCR1 gene and its association with hepatitis B infected patients in Saudi Arabia. Annals of Hepatology 2013; 12:220-7.
3. Al-Qahtani A., Alarifi S, Al-Okail M, Hussain Z., Abdo A, Sanai F, et al RANTES gene polymorphisms (-403G>A and -28C>G) associated with hepatitis B virus infection in a Saudi population. Genetics and Molecular Research 2012; 11: 855-62.
4. Bardens A, Drink T, Stieler J., Prange R. Alix regulates egress of hepatitis B virus naked capsid particles in an ESCRT-independent manner. Cellular Microbiology 2011; 13:602-19.
5. Barone M, Spano D, D'Apolito M, Centra M, Lasalandra C., Capasso M, et al Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. Molecular Medicine 2006; 12:115-23. (Pubitemid 44454099)
6. Beck J, Nassal M. Hepatitis B virus replication. World Journal of Gastroenterology 2007; 13:48-64. (Pubitemid 46165462)
7. Blumberg BS, Alter HJ, Visnich S. A "new," antigen in leukemia sera. JAMA 1965; 191:541-6.
8. Bosch FX, Ribes J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:S5-16.
9. Braconi C, Patel T. MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology 2008; 47:1807-9. (Pubitemid 351945546)
10. Carlson CS, Eberle MA, Rieder M.J., Smith JD, Kruglyak L, Nickerson DA Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nature Genetics 2003; 33:518-21. (Pubitemid 36390016)
11. Chen J, Wang L, Li Y., Cai B, Fu Y, Liao Y., et al Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. PLoS ONE 2012; 7:e50787.
12. Chen J, Yin J, Tan X., Zhang H, Zhang H, Chen B., et al Improved multiplex-PCR to identify hepatitis B virus genotypes A-F and subgenotypes B1, B2, C1 and C2. Journal of Clinical Virology 2007; 38:238-43. (Pubitemid 46275526)
13. Chen X, Ba Y, Ma L., Cai X, Yin Y, Wang K., et al Characterization of microRNAs in serum: a novel class ofbiomarkers for diagnosis of cancer and other diseases. Cell Research 2008; 18:997-1006.
14. Cheng HR, Liu CJ, Tseng T.C., Su TH, Yang HI, Chen CJ, et al Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS ONE 2013; 8:e53008.
15. Chisari F, Klopchin K, Morijama T, Pasquinelli C, Dunsford HA, Sell S, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59:1145-56. (Pubitemid 20024625)
16. Chu CJ, Hussain M, Lok AS Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002a; 36:1408-15. (Pubitemid 35407438)
17. Chu CJ, Lok AS Clinical significance of hepatitis B virus genotypes. Hepatology 2002b; 35:1274-6. (Pubitemid 34454026)
18. Chunsuttiwat S, Biggs BA, Maynard J.E., Thammapormpilas P., O-Prasertsawat M. Comparative evaluation of a combined DTP-HB vaccine in the EPI in Chiangrai Province, Thailand. Vaccine 2002; 21:188-93. (Pubitemid 35346813)
19. Colonno RJ, Rose R, Baldick C.J., Levine S., Pokornowski K, Yu CF, et al Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44:1656-65. (Pubitemid 44953670)
20. Cougot D, Allemand E, Rivière L, Benhenda S, Duroure K, Levillayer F, et al. Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. Signal Transduction 2012; 5:ra1.
21. Dandri M, Burda MR, Burkle A, Zuckerman D.M., Will H., Rogler CE, et al. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly (ADP-ribosyl)ation. Hepatology 2002; 35:217-23. (Pubitemid 34032563)
22. Delaney WEJ 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrobial Agents and Chemotherapy 2006; 50:2471-7. (Pubitemid 43993188)
23. Dienstag JL, Goldin RD, Heathcote E.J., Hann HW, Woessner M, Stephenson SL, et al Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-17. (Pubitemid 36055344)
24. Dufour DR, Lott JA, Nolte F.S., Gretch DR, Koff RS, Seeff LB Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clinical Chemistry 2000; 46:2027-49.
25. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008; 48:335-52.
26. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Letters 2007; 253:157-70. (Pubitemid 46809787)
27. Fitzsimons D, Francois G, Hall A., McMahon B, Meheus A, Zanetti A., et al Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005; 23:4158-66. (Pubitemid 40814591)
28. Fleischer RD, Lok AS Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. Journal of Hepatology 2009; 51:787-91.
29. Francois G, Duclos P, Margolis H., Lavanchy D, Siegrist CA, Meheus A, et al Vaccine safety controversies and the future of vaccination programs. Pediatric Infectious Disease Journal 2005; 24:953-61. (Pubitemid 41689596)
30. Fu LL, Wen X, Bao J.K., Liu B. MicroRNA-modulated autophagic signaling networks in cancer. International Journal of Biochemistry and Cell Biology 2012; 44:733-6.
31. Fung SK, Chae HB, Fontana R.J., Conjeevaram H., Marrero J, Oberhelman K, et al Virologic response and resistance to adefovir in patients with chronic hepatitis B. Journal of Hepatology 2006; 44:283-90. (Pubitemid 43069209)
32. Galibert F, Mandart E, Fitoussi F., Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979; 281:646-50. (Pubitemid 10249039)
33. Ganem D, Prince AM Hepatitis B virus infection - natural history and clinical consequences. New England Journal of Medicine 2004; 350:1118-29. (Pubitemid 38298992)
34. Ganova-Raeva L., Ramachandran S, Honisch C., Zhang H, Fan Z. Granzyme H of cytotoxic lymphocytes is required for clearance of the hepatitis B virus through cleavage of the hepatitis B virus X protein. Journal of Immunology 2012; 188:824-31.
35. Gao B, Wang H, Lafdil F., Feng D. STAT proteins-key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. Journal of Hepatology 2012; 57:430-41.
36. Hayashi K, Katano Y, Takeda Y., Honda T, Ishigami M, Itoh A., et al Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. Journal of Medical Virology 2007; 79:366-73. (Pubitemid 46355435)
37. Heindryckx F, Colle I, Vlierberghe HV Experimental mouse models for hepatocellular carcinoma research. International Journal of Experimental Pathology 2009; 90:367-86.
38. Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. Journal of Biomedicine and Biotechnology 2011; 2011:451694.
39. Hu X, Margolis HS, Purcell RH, Ebert J, Robertson BH. Identification of hepatitis B virus indigenous to chimpanzees. Proceedings of the National Academy of Sciences of the United States of America 2000; 97:1661-4. (Pubitemid 30118499)
40. Huang Y, Tong S, Tai A.W., Hussain M., Lok AS Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology 2011; 141:1412-21.
41. Iino S, Toyota J, Kumada H., Kiyosawa K, Kakumu S, Sata M., et al The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. Journal of Viral Hepatitis 2005; 12:300-6. (Pubitemid 40638038)
42. Iloeje UH, Yang HI, Chen CJ Natural history of chronic hepatitis B: what exactly has REVEAL revealed. Liver International 2012; 32:1333-41.
43. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S., Akarca US, Cakaloglu Y, et al Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9. (Pubitemid 40091801)
44. Kann M, Schmitz A, Rabe B. Intracellular transport of hepatitis B virus. World Journal of Gastroenterology 2007; 13:39-47. (Pubitemid 46165461)
45. Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Review of Gastroenterology and Hepatology 2008; 2:553-62.
46. Kim JS, Rho B, Lee T.H., Lee JM, Kim SJ, Park JH The interaction of hepatitis B virus X protein and protein phosphatase type 2 Calpha and its effect on IL-6. Biochemical and Biophysical Research Communications 2006; 351:253-8. (Pubitemid 44635434)
47. Kim SY, Lee PY, Shin H.J., Kim do H, Kang S, Moon H.B., et al Proteomic analysis of liver tissue from HBx-transgenic mice at early stages of hepatocarcinogenesis. Proteomics 2009; 9:5056-66.
48. Knoll S, Fürst K, Thomas S., Villanueva Baselga S, Stoll A, Schaefer S., et al Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC. Cell Cycle 2011; 10:3554-65.
49. Korba BE, Cote P, Hornbuckle W., Tennant BC, Gerin JL Treatment of chronic wood-chuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 2000; 31:1165-75. (Pubitemid 30233243)
50. Ladeiro Y, Couchy G, Balabaud C., Bioulac-Sage P, Pelletier L, Rebouissou S., et al MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47:1955-63. (Pubitemid 351952843)
51. Lai CL, Gane E, Liaw Y.E., Hsu CW, Thongsawat S, Wang Y, et al Telbivudine versus lamivudine in patients with chronic hepatitis B. New England Journal of Medicine 2007; 357:2576-88. (Pubitemid 350294224)
52. Lai CL, Leung N, Teo E.K., Tong M., Wong F, Hann HW, et al A1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-36. (Pubitemid 41096641)
53. Lakner AM, Bonkovsky HL, Schrum LW microRNAs: fad or future of liver disease. World Journal of Gastroenterology 2011; 17:2536-42.
54. Lee DK, Park SH, Yi Y, Choi S.G., Lee C., Parks WT, et al The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes and Development 2001; 15:455-66. (Pubitemid 32187006)
55. Lee JH, Yoon JH, Cho E.J., Yang HJ, Jang ES, Kwak MS, et al Simple scoring system predicting genotypic resistance during rescue therapy for lamivudine-resistant chronic hepatitis B. Journal of Clinical Gastroenterology 2012; 46:243-50.
56. Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. Journal of Pharmaceutical Sciences 2008; 97:1109-34.
57. Liang TJ, Ghany M. Hepatitis B. E Antigen - the dangerous endgame of hepatitis B. New England Journal of Medicine 2002; 347:208-10.
58. Liang TJ. Hepatitis B: the virus and disease. Expert Review of Anti-infective Therapy 2009; 7:309-20.
59. Liaw YF, Chu CM Hepatitis B virus infection. Lancet 2009; 373:582-92.
60. Liaw YF, Sung JJ, Chow W.C., Farrell G., Lee CZ, Yuen H, et al Lamivudine for patients with chronic hepatitis B and advanced liver disease. New England Journal of Medicine 2004; 351:1521-31.
61. Lim SG, Ng TM, Kung N, Krastev Z., Volfova M, Husa P, et al A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Archives of Internal Medicine 2006; 166:49-56. (Pubitemid 43063841)
62. Liu Y, Tong Z, Li T., Chen Q, Zhuo L, Li W., et al Hepatitis B virus X protein stabilizes amplified in breast cancer 1 protein and cooperates with it to promote human hepatocellular carcinoma cell invasiveness. Hepatology 2012a; 56: 1015-24.
63. Liu H, Yuan Y, Guo H., Mitchelson K, Zhang K, Xie L., et al Hepatitis B virus encoded X protein suppresses apoptosis by inhibition of the caspase-independent pathway. Journal of Proteome Research 2012b; 11:4803-13.
64. Lu JW, Hsia Y, Yang W.Y., Lin YI, Li CC, Tsai TF, et al Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis 2012; 33:209-19.
65. Lucifora J, Arzberger S, Durantel D., Belloni L, Strubin M, Levrero M., et al Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. Journal of Hepatology 2011; 55:996-1003.
66. Lutgehetmann M, Volz T, Kopke A., Broja T, Tigges E, Lohse A.W., et al In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010; 52:16-24.
67. Lyons S, Sharp C, LeBreton M., Djoko CF, Kiyang JA, Lankester F, et al Species association of hepatitis B virus (HBV) in non-human apes; evidence for recombination between gorilla and chimpanzee variants. PLoS ONE 2012; 7:e33430.
68. Ma J, Sun T, Park S, Liu J. The role of hepatitis B virus X protein is related to its differential intracellular localization. Acta Biochimica et Biophysica Sinica (Shanghai) 2011; 43:583-8.
69. MacDonald DM, Holmes EC, Lewis J.C., Simmonds P. Detection of hepatitis B virus infection in wild-born chimpanzees (Pan troglodytes verus): phylogenetic relationships with human and other primate genotypes. Journal of Virology 2000; 74:4253-7. (Pubitemid 30214432)
70. Magiorkinis EN, Magiorkinis GN, Paraskevis DN, Hatzakis AE. Re-analysis of a human hepatitis B virus (HBV) isolate from an East African wild born Pan troglodytes schweinfurthii: evidence for interspecies recombination between HBV infecting chimpanzee and human. Gene 2005; 349:165-71.
71. Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proceedings of the National Academy of Sciences of the United States of America 2005; 102:1139-44. (Pubitemid 40170739)
72. Michalak TI, Zhang H, Churchill N.D., Larsson T., Johansson NG, Oberg B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrobial Agents and Chemotherapy 2009; 53:3803-14.
73. Momin B, Richardson L. An analysis of content in comprehensive cancer control plans that address chronic hepatitis B and C virus infections as major risk factors for liver cancer. Journal of Community Health 2012; 37:912-6.
74. Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. Journal of Gastroenterology 2001; 36:651-60. (Pubitemid 33040937)
75. Neurath AR, Kent SB, Strick N. Detection of antiviral antibodies with predetermined specificity using synthetic peptide-beta-lactamase conjugates: application to antibodies specific for the preS region of the hepatitis B virus envelope proteins. Journal of General Virology 1986; 67:453-61. (Pubitemid 16158585)
76. Newbold JE, Xin H, Tencza M., Sherman G, Dean J, Bowden S., et al The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. Journal of Virology 1995; 69:3350-7.
77. Ng LF, Chan M, Chan S.H., Cheng PC, Leung EH, Chen W, et al Host heterogeneous ribonucleoprotein K (hnRNPK) as a potential target to suppress hepatitis B virus replication. PLoS Medicine 2005; 2:e163.
78. Orito E, Mizokami M, Sakugawa H., Michitaka K, Ishikawa K, Ichida T., et al A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes Band C. Hepatology 2001; 33:218-23. (Pubitemid 32016905)
79. Pedersen IM, Cheng G, Wieland S., Volinia S, Croce CM, Chisari F.V., et al Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449:919-22. (Pubitemid 47598616)
80. Perlman D, Hu J. Duck hepatitis B virus virion secretion requires a double-stranded DNA genome. Journal of Virology 2003; 77:2287-94. (Pubitemid 36110045)
81. Protzer U, Seyfried S, Quasdorff M, Sass G, Svorcova M, Webb D, et al. Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology 2007; 133:1156-65. (Pubitemid 47500115)
82. Qadri I, Fatima K, AbdeL-Hafiz H. Hepatitis B virus X protein impedes the DNA repair via its association with transcription factor, TFIIH. BMC Microbiology 2011; 11:48.
83. Rahmani Z, Huh KW, Lasher R, Siddiqui A. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel HVDAC3, and alters its transmembrane potential. Journal of Virology 2000; 74:2840-6. (Pubitemid 30117595)
84. Rapicetta M, D'Ugo E, Argentini C, Catone S., Canitano A, Giuseppetti R, et al New perspectives for hepatitis B vaccines and immunization. Vaccine 2009; 27:3271-5.
85. Ren S, Nassal M. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. Journal of Virology 2001; 75:1104-6.
86. Robek MD, Boyd BS, Chisari FV Lambda interferon inhibits hepatitis B and C virus replication. Journal of Virology 2005; 79:3851-4. (Pubitemid 40327973)
87. Roggendorf M, Yang D, Lu M. The woodchuck: a model for therapeutic vaccination against hepadnaviral infection. Pathologie Biologie 2010; 58:308-14.
88. Sa-Nguanmoo P., Rianthavorn P, Amornsawadwattana S., Poovorawan Y. Hepatitis B virus infection in non-human primates. Acta Virologica 2009; 53:73-82.
89. Saniova B, Drobny M, Lehotsky J, Sulaj M, Schudichova J. Biochemical and clinical improvement of cytotoxic state by amantadine sulphate. Cellular and Molecular Neurobiology 2006; 26:1475-82. (Pubitemid 44924060)
90. Schmitt S, Glebe D, Alving K., Lochnit G, Linder D, Geyer R. Analysis of the pre- S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. Journal of Biological Chemistry 1999; 274:11945-57.
91. Seeger C, Ganem D, Varmus HE Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986; 232:477-84. (Pubitemid 16052356)
92. Sherman M, Yurdaydin C, Simsek H., Silva M, Liaw YF, Rustgi V.K., et al Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48:99-108. (Pubitemid 351975535)
93. Sumi H, Yokosuka O, Seki N., Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37:19-26. (Pubitemid 36042140)
94. Sung WK, Lu Y, Lee C.W., Zhang D., Ronaghi M, Lee CG Deregulated direct targets of the hepatitis B virus (HBV) protein, HBx, identified through chromatin immunopre-cipitation and expression microarray profiling. Journal of Biological Chemistry 2009; 284:21941-54.
95. Tang H, Da L, Mao Y., Li Y, Li D, Xu Z., et al Hepatitis B virus X protein sensitizes cells to starvation-induced autophagy via up-regulation of beclin 1 expression. Hepatology 2009; 49:60-71.
96. Tong AP, Gou LT, Lau Q.C., Chen B., Zhao X, Li J, et al Proteomic profilingidentifies aberrant epigenetic modifications induced by hepatitis B virus X protein. Journal of Proteome Research 2009; 8:1037-46.
97. Truelove AL, Oleksyk TK, Shrestha S, Thio CL, Goedert JJ, Donfield SM, et al. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. International Journal of Immunogenetics 2008; 35:255-64. (Pubitemid 351678694)
98. Urban S, Schulze A, Dandri M., Petersen J. The replication cycle of hepatitis B virus. Journal of Hepatology 2010; 52:282-4.
99. Valenzuela P, Gray P, Quiroga M., Zaldivar J, Goodman HM, Rutter WJ Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature 1979; 280:815-9. (Pubitemid 9254040)
100. van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44:318-25. (Pubitemid 44214870)
101. van Zonneveld M., Honkoop P, Hansen B.E., Niesters HG, Darwish Murad S, de Man RA, et al Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39:804-10. (Pubitemid 38337661)
102. Vartanian JP, Pineau P, Henry M., Hamilton WD, Muller MN, Wrangham RW, et al Identification of a hepatitis B virus genome in wild chimpanzees (Pan troglodytes schweinfurthi) from East Africa indicates a wide geographical dispersion among equatorial African primates. Journal of Virology 2002; 76:11155-8. (Pubitemid 35176234)
103. Vivekanandan P, Thomas D, Torbenson M. Methylation regulates hepatitis B viral protein expression. Journal of Infectious Diseases 2008; 199:1286-91.
104. Volz T, Allweiss L, Barek M.B., Warlich M., Lohse AW, Pollok JM, et al The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with Hepatitis B virus. Journal of Hepatology 2012, p ii: S0168-8278(12)00956-7.
105. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009; 50:1152-61.
106. Wang C, Yang W, Yan H.X., Luo T., Zhang J, Tang L, et al Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology 2012a; 55:108-20.
107. Wang F, Zhou H, Yang Y., Xia X, Sun Q, Luo J, et al. Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncology Reports 2012b; 27:1170-6.
108. Wang HY, Chien MH, Huang H.P., Chang HC, Wu CC, Chen PJ, et al Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. Journal of Virology 2010a; 84:3454-63.
109. Wang J, Liu X, Wu H., Ni P, Gu Z, Qiao Y., et al CREB upregulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Research 2010b; 38:5366-83.
110. Wang P, Guo QS, Wang Z.W., Qian HX HBx induces HepG-2 cells autophagy through PI3K/Akt-mTOR pathway. Molecular and Cellular Biochemistry 2013; 372:161-8.
111. Wang Q, Na B, Ou J.H., Pulliam L., Yen TSB. Hepatitis B virus alters the antioxidant system in transgenic mice and sensitizes hepatocytes to fas signaling. PLoS ONE 2012c; 7:e36818.
112. Wang Q Schwarzenberger P, Yang F, Zhang J., Su J, Yang C, et al. Experimental chronic hepatitis B infection of neonatal tree shrews (Tupaia belangeri chinensis): A model to study molecular causes for susceptibility and disease progression to chronic hepatitis in humans. Journal of Virology 2012d; 9:170.
113. Wang Y, Xu P, Zhu D., Zhang S, Bi Y, Hu Y., et al Association of polymorphisms of cytokine and TLR-2 genes with long-term immunity to hepatitis B in children vaccinated early in life. Vaccine 2012e; 30:5708-13.
114. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009; 49:1132-40.
115. Xia L, Tian D, Huang W., Wang J, Zhang Y, Hu H., et al Upregulation of IL-23 expression inpatients with chronic hepatitis Bis mediated by the HBx/ERK/NF-(B pathway. Journal of Immunology 2012; 188:753-64.
116. Xie J, Zhang Y, Zhang Q, Yin J, Pu R, Shen Q, et al. Interaction of signal transducer and activator of transcription 3 polymorphisms with HBV mutations in hepatocellular carcinoma. Hepatology 2013., http://dx.doi.org/10. 1002/hep.26302.
117. Xie N, Huang K, Zhang T., Lei YL, Liu R, Wang K, et al Comprehensive proteomic analysis of host cell lipid rafts modified by HBV infection. Journal of Proteomics 2012; 75:725-39.
118. Xu J, Liu H, Chen L., Wang S, Zhou L, Yun X., et al Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. Gastroenterology 2012; 143:199-212.
119. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholatecotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1:e00049.
120. Yang EB, Cao J, Su J.J., Chow P. The tree shrews: useful animal models for the viral hepatitis and hepatocellular carcinoma. Hepato-Gastroenterology 2005; 52: 613-6. (Pubitemid 40469479)
121. Yuen MF, Lai CL Adefovir dipivoxil in chronic hepatitis B infection. Expert Opinion on Pharmacotherapy 2004; 5:2361-7.
122. Yuen MF, Lee SH, Kang H.M., Kim CR, Kim J, Ngai V, et al Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. Antimicrobial Agents and Chemotherapy 2009; 53: 1779-85.
123. Zhang T, Xie N, He W.F., Liu R., Lei YL, Chen Y, et al An integrated proteomics and bioinformatics analyses of Hepatitis B Virus X protein and identification of a novel interactorapoA-I. Journal of Proteomics 2013; 84:92-105.
124. Zhang X, Hong X, Deng G., Bai X. Single nucleotide polymorphisms and functional analysis of class II transactivator(CIITA) promoter IV in persistent HBV infection. Journal of Clinical Virology 2007; 40:197-201. (Pubitemid 47552931)
125. Zhang Z, Sun E, Ou J.H., Liang TJ Inhibition of cellular proteasome activities mediates HBX-independent hepatitis B virus replication in vivo. Journal of Virology 2010; 84:9326-31.
126. Zhou J, Smith DK, Lu L, Poon V.K., Ng F., Chen DQ, et al A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection. Journal of Viral Hepatitis 2009; 16:45-52.
127. Zhou XL, Sullivan GJ, Sun P, Park IH Humanized murine model for HBV and HCV using human induced pluripotent stem cells. Archives of Pharmacal Research 2012; 35:261-9.
128. Zhu YL, Dutschman DE, Liu S.H., Bridges EG, Cheng YC Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)- 5fluorocytidine. Antimicrobial Agents and Chemotherapy 1998; 42:1805-10. (Pubitemid 28311583)
129. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. Journal of Hepatology 2005; 42:302-8. (Pubitemid 40254242)
130. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137:1593-608.